Rubicon Research Limited (RUBICON) — Board Meeting
Rubicon Research Limited announced on May 29, 2026, that its board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with an unmodified audit opinion from Deloitte Haskins & Sells LLP. The board recommended a final dividend of ₹1.50 per share (face value ₹1) for FY2026, subject to shareholder approval at the upcoming AGM, with payment to occur within 30 days of declaration. The financial statements, including total income of ₹17,616.83 crores and net profit of ₹2,467.35 crores, were disclosed as compliant with SEBI LODR and Ind AS. Documents are available on the company's website under the Investors section.
About Rubicon Research Limited (RUBICON)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when RUBICON files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track RUBICON — Free💡 Ask AI about this filing
📊 More RUBICON filings
- Announcement — 20 July 2026 Rubicon Research Limited announced on July 20, 2026, that its Nomination and Remuneration Committee ...
- Announcement — 3 July 2026 Rubicon Research Limited disclosed that the US FDA conducted an unannounced inspection of its newly ...
- Financial Results — 29 June 2026 Rubicon Research Limited announced that its trading window will close on July 1, 2026, ahead of the ...
- 🔴 Announcement — 19 June 2026 No summary available
- 🔴 Announcement — 10 June 2026 No summary available
🔥 Also filed on 29 May 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when RUBICON files new disclosures
Track RUBICON filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track RUBICON — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research